Piramal Pharma Solutions et NP2 vont conclure la phase de développement du cyclophosphamide le mois prochain

cyclophosphamideNeutral

AI Analysis

Summary

Piramal Pharma Solutions and NP2 are expected to complete the development phase of cyclophosphamide, a generic cancer drug, in October 2026 at Piramal's sterile injectable manufacturing facility.

Importance:3/10

Sentiment:

0.00

generic drug developmentoncologymanufacturingpartnership

Read the original article

Published by PR Newswire Biotech on October 1, 2026 12:44 PM

Read Original